AIM ImmunoTech (AIM) Long-Term Investments (2010 - 2021)
AIM ImmunoTech's (AIM) quarterly Long-Term Investments came in at $15.8 million in Q3 2021, up 6.57% YoY from $14.8 million in Q3 2020, and down 2.01% on a QoQ basis from $16.1 million in Q2 2021.
AIM ImmunoTech (AIM) Long-Term Investments (2010 - 2021) Analysis & Trends
AIM ImmunoTech (AIM) has 4 years of Long-Term Investments data on file, last reported at $15.8 million in Q3 2021.
- Quarterly Long-Term Investments rose 6.57% year-over-year to $15.8 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $15.8 million (up 6.57% YoY) and the FY2020 annual result came in at $15.4 million, changed N/A from the prior year.
- Long-Term Investments retreated to $15.8 million in Q3 2021, from $16.1 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $16.1 million in Q2 2021 to a low of $3.0 million in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 15.81 Mn |
| Jun 30, 2021 | 16.14 Mn |
| Mar 31, 2021 | 13.66 Mn |
| Dec 31, 2020 | 15.42 Mn |
| Sep 30, 2020 | 14.84 Mn |
| Jun 30, 2020 | 5.31 Mn |
| Mar 31, 2020 | 3.01 Mn |
| Dec 31, 2011 | 1.96 Mn |
| Dec 31, 2010 | 8.78 Mn |